While primary RAD51D mutations initially sensitize ovarian cancer cells to PARP inhibitors, Kondrashova et al. reported that secondary mutations of both RAD51D and RAD51C conferred acquired PARP inhibitor resistance similar to the secondary mutations of BRCA1 or BRCA2 [190]. This evidence concerns the gene BRCA2 and ovarian carcinoma.